Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Processes 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × MRX-2843 × 1 year × Clear all
NCT03510104 2026-01-08

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

Meryx, Inc.

Phase 1 Completed
42 enrolled

Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡